Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

Yasuyoshi Hatayama; Yutaro Yamaoka; Takeshi Morita; Sundararaj Stanleyraj Jeremiah; Kei Miyakawa; Mayuko Nishi; Yayoi Kimura; Makoto Mitsunaga; Tadayuki Iwase; Hirokazu Kimura; Naoki Yamamoto; Akifumi Takaori-Kondo; Hideki Hasegawa; Akihide Ryo

doi:10.3390/v14102153

Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

Yasuyoshi Hatayama
, Yutaro Yamaoka
, Takeshi Morita
, Sundararaj Stanleyraj Jeremiah
, Kei Miyakawa
, Mayuko Nishi
, Yayoi Kimura
, Makoto Mitsunaga
, Tadayuki Iwase
, Hirokazu Kimura
, Naoki Yamamoto
, Akifumi Takaori-Kondo
, Hideki Hasegawa
, Akihide Ryo

Yokohama City University

Research output: Contribution to journal › Article › peer-review

Abstract

Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells.

Original language	English
Article number	2153
Journal	Viruses
Volume	14
Issue number	10
DOIs	https://doi.org/10.3390/v14102153
Publication status	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3390/v14102153

Cite this

Hatayama, Y., Yamaoka, Y., Morita, T., Jeremiah, S. S., Miyakawa, K., Nishi, M., Kimura, Y., Mitsunaga, M., Iwase, T., Kimura, H., Yamamoto, N., Takaori-Kondo, A., Hasegawa, H., & Ryo, A. (2022). Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy. Viruses, 14(10), Article 2153. https://doi.org/10.3390/v14102153

@article{f40338e1d54940489d71e5ff1181b696,

title = "Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy",

abstract = "Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells.",

author = "Yasuyoshi Hatayama and Yutaro Yamaoka and Takeshi Morita and Jeremiah, \{Sundararaj Stanleyraj\} and Kei Miyakawa and Mayuko Nishi and Yayoi Kimura and Makoto Mitsunaga and Tadayuki Iwase and Hirokazu Kimura and Naoki Yamamoto and Akifumi Takaori-Kondo and Hideki Hasegawa and Akihide Ryo",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = oct,

doi = "10.3390/v14102153",

language = "English",

volume = "14",

journal = "Viruses",

issn = "1999-4915",

number = "10",

}

Hatayama, Y, Yamaoka, Y, Morita, T, Jeremiah, SS, Miyakawa, K, Nishi, M, Kimura, Y, Mitsunaga, M, Iwase, T, Kimura, H, Yamamoto, N, Takaori-Kondo, A, Hasegawa, H & Ryo, A 2022, 'Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy', Viruses, vol. 14, no. 10, 2153. https://doi.org/10.3390/v14102153

TY - JOUR

T1 - Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

AU - Hatayama, Yasuyoshi

AU - Yamaoka, Yutaro

AU - Morita, Takeshi

AU - Jeremiah, Sundararaj Stanleyraj

AU - Miyakawa, Kei

AU - Nishi, Mayuko

AU - Kimura, Yayoi

AU - Mitsunaga, Makoto

AU - Iwase, Tadayuki

AU - Kimura, Hirokazu

AU - Yamamoto, Naoki

AU - Takaori-Kondo, Akifumi

AU - Hasegawa, Hideki

AU - Ryo, Akihide

PY - 2022/10

Y1 - 2022/10

N2 - Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells.

AB - Human T-cell leukemia virus type 1 (HTLV-1), a retrovirus, causes adult T-cell leukemia-lymphoma, HTLV-1 associated myelopathy/tropical spastic paraparesis, and HTLV-1 uveitis. Currently, no antiretroviral therapies or vaccines are available for HTLV-1 infection. This study aimed to develop an antibody against the HTLV-1 envelope protein (Env) and apply it to a near-infrared photoimmuno-antimicrobial strategy (NIR-PIAS) to eliminate HTLV-1 infected cells. We established mouse monoclonal antibodies (mAbs) against HTLV-1 Env by immunization with a complex of liposome and the recombinant protein. Detailed epitope mapping revealed that one of the mAbs bound to the proline-rich region of gp46 and exhibited no obvious neutralizing activity to inhibit viral infection. Instead, the mAb was rarely internalized intracellularly and remained on the cell surface of HTLV-1-infected cells. The antibody conjugated to the photosensitive dye IRDye700Dx recognized HTLV-1 infected cells and killed them following NIR irradiation. These results suggest that the novel mAb and NIR-PIAS could be developed as a new targeted therapeutic tool against HTLV-1 infected cells.

UR - http://dx.doi.org/10.3390/v14102153

U2 - 10.3390/v14102153

DO - 10.3390/v14102153

M3 - Article

SN - 1999-4915

VL - 14

JO - Viruses

JF - Viruses

IS - 10

M1 - 2153

ER -

Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this